Novo's Wegovy and Ozempic Removed from US FDA Shortage List: Compounders Alerted

The US Food and Drug Administration has removed semaglutide from its shortage list, signifying enhanced availability of Ozempic and Wegovy for patients. Novo Nordisk is now capable of meeting current and future demand for its medications in the U.S., per the FDA's announcement. Compounders have been cautioned by the FDA to cease the production of the drug, with 503A compounders given until April 22 and 503B compounders until May 22. Patients may still encounter some supply disruptions during the distribution process despite the improved availability of Ozempic and Wegovy.